Skip to main content

Specialty Pharmacy

  • Diplomat: Second PBM acquisition in 2 weeks signals shift to ‘disruptive’ approach

    Diplomat Pharmacy is continuing its growth and diving head-first into the pharmacy benefits management business with its plan to acquire Leehar Distributors, which does business as LDI Integrated Pharmacy Services. The acquisition of LDI marks Diplomat’s second PBM acquisition this month, having acquired National Pharmaceutical Services on Nov. 6. 

  • Making supplements sustainable
    The Marine Stewardship Council is looking to ensure that fish and krill oil supplement makers can capture an increasing number of consumers interested in knowing where their supplements came from.

  • Mylan intros generic Clolar for injection

    PITTSBURGH — Mylan has introduced its generic of Clolar (clofarabine 1 mg/ml) injection. The drug is indicated to treat patients ages 1 year to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior treatment regimens.

    The latest launch adds to Mylan’s oncology portfolio, which it said contains more than 40 products. Mylan’s Clolar generic will be available in single-dose vials.

    According to data from IQVIA (formerly QuintilesIMS), the drug had U.S. sales of $53 million for the 12 months ended Sept. 30.
     

  • McKesson acquires RxCrossroads from CVS Health

    SAN FRANCISCO — McKesson on Monday announced that it has signed a definitive agreement to purchase RxCrossroads from CVS Health in a deal valued at $735 million. The acquisition is expected to close in the fourth quarter of fiscal 2018, subject to customary closing conditions, including necessary regulatory clearances.

  • Diplomat accompanies solid Q3 results with another acquisition

    FLINT, Mich. — Diplomat Pharmacy this week is demonstrating how it is continuing its growth — both organically and through acquisitions. Alongside its solid third-quarter results, the company announced its acquisition of Pharmaceutical Technologies, which does business as National Pharmaceutical Services.

  • AstraZeneca gets FDA nod for Calquence

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new lymphoma treatment from AstraZeneca. The company announced this week that its Calquence (acalabrutinib) had been approved to treat patients with mantle cell lymphoma in patients who have received at least one prior therapy.

  • Diplomat names former Walgreens exec EVP sales and payer strategies

    FLINT, Mich. — Diplomat Pharmacy has a new member of its executive leadership team who brings with her more than a quarter-century of industry experience. The company has named Robyn Peters its new EVP sales and payer strategies, a role in which she will oversee payer and business development strategies, as well as sales and account management.

  • FDA approves Yescarta from Gilead's Kite

    FOSTER CITY, Calif. — The Food and Drug Administration has approved the first chimeric antigen receptor T cell, or CAR T, therapy for patients with certain types of lymphoma. Yescarta, from Gilead’s recently acquired company Kite, was approved to treat relapsed or refractory large B-cell lymphoma following two or more lines of systemic therapy.

X
This ad will auto-close in 10 seconds